Skip to main content
Clinical Trials/NCT03061786
NCT03061786
Recruiting
Not Applicable

Prognosis of Acute Kidney Injury:China Collaborative Study on AKI(CCS-AKI)Study

XinLing Liang1 site in 1 country1,000,000 target enrollmentJanuary 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Kidney Injury
Sponsor
XinLing Liang
Enrollment
1000000
Locations
1
Primary Endpoint
estimated glomerular filtration rate decline
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Acute kidney injury (AKI) is a common clinical syndrome, especially in the hospital patients. AKI is recognized as an important risk factor for incident chronic kidney disease, accelerated progression to end-stage renal disease,and increased risk of short-term and long-term mortality.This study is to observe the prognosis of hospitalized patients with AKI in China.

Registry
clinicaltrials.gov
Start Date
January 2017
End Date
December 2027
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
XinLing Liang
Responsible Party
Sponsor Investigator
Principal Investigator

XinLing Liang

Director of Division of Nephrology and Blood Purification Center of Guangdong General Hospital

Guangdong Provincial People's Hospital

Eligibility Criteria

Inclusion Criteria

  • clinically diagnosed with acute kidney injury, according to KDIGO criteria

Exclusion Criteria

  • Nephrectomy
  • Kidney transplantation
  • Peak serum creatinine of less than 53µ mol/L
  • Serum creatinine decrease after amputation
  • Patients died during hospitalization
  • End-stage kidney disease(chronic kidney disease stage 5)
  • malnutrition

Outcomes

Primary Outcomes

estimated glomerular filtration rate decline

Time Frame: 2 years

\>50% baseline

New cardiovascular events

Time Frame: 5 years

All-cause mortality

Time Frame: 5 years

Chronic kidney disease classification upgrade

Time Frame: 5 years

Secondary Outcomes

  • Rehospitalization(5 years)
  • AKI recovery(5 years)

Study Sites (1)

Loading locations...

Similar Trials